 |
 |
 |
 |
 |
 |
 |
 |
|
ImmuneRegen’s current focus is to develop drug candidates for regenerating or strengthening the human immune system, in part, through stimulation of human adult stem cells. Recent efforts have identified a stem cell activity for our lead candidate Homspera®, and it is the belief of Management that this finding underlies some of the beneficial effects previously reported in potential applications such as radiation exposure, infectious disease and wound healing.
Our patents, patent applications and continued research are partially derived from academic discoveries surrounding the function of Substance P, a naturally-occurring protein found throughout the body that acts in both the neuronal and immune systems. In the course of research on Substance P, scientists created a number of synthetic analogues of Substance P for study. One of these structural derivatives, which we have named Homspera, is the basis of our drug development efforts and intellectual property. We have adopted additional nomenclature for Homspera depending on the application and the potential for differences in formulations, administration modes and future market opportunities. Specifically, Radilex® is the trade name associated with possible treatments for acute radiation exposure, while Viprovex® is being used for potential treatments in areas such as infectious disease, vaccine adjuvancy and chemical exposures. Both Radilex and Viprovex have the same active ingredient as Homspera.
The initial pre-clinical applications we are researching include:
All of our product candidates are in the pre-clinical stages of development. They have only been introduced to the FDA via our pre-IND filings, submissions to which the FDA offers no judgment thereon. To date we have been issued two Pre-Investigational New Drug (PIND) numbers by the U.S. Food & Drug Administration (FDA). One is for the potential use of Radilex in the treatment of acute radiation syndrome and one is for the potential use of Viprovex in the treatment of avian influenza.
We are continuing to explore the capabilities of Homspera by striving to better understand the molecular mechanisms for this compound in order to further our developmental efforts in both existing programs as well as potential future applications.
